May 22, 2023

Relapsing multiple sclerosis patients treated with ocrelizumab show similar brain volume loss rates to healthy controls. Inflammation and neurodegeneration are the characteristic features of multiple sclerosis (MS). Disease-modifying therapies classically used to treat inflammation have also been shown to be beneficial in slowing the rate of brain volume loss (BVL) due to neurodegeneration.  Ocrelizumab, a...

Brain volume loss is independent of disease activity in multiple sclerosis and might respond to early administration of disease-modifying therapy. Neurodegeneration is a characteristic feature of multiple sclerosis (MS). Magnetic resonance imaging (MRI) features, like brain and spinal cord atrophy and MS lesion T2 volume, are associated with neurologic decline and disability. Irreversible brain volume...

Dupilumab is associated with greater improvement in asthma exacerbations than omalizumab and mepolizumab. Multiple monoclonal antibodies (mAbs) are currently approved for asthma treatment. All of these improve outcomes in asthma patients who cannot be controlled with conventional therapy. However, only limited data is available regarding their comparative effectiveness, thus restricting opportunities to optimize patient selection...

Itraconazole as a treatment for severe persistent asthma results in a reduction in bronchial wall thickness and an improvement in symptoms and pulmonary function. Severe persistent asthma (SPA) represents five to ten percent of the total asthma population. Long-term use of inhaled corticosteroids in SPA can result in fungal colonization and inflammation. Various inflammatory mediators...